●Accelerated and upgraded innovation●Empowerment through partnerships●Two consecutive years of profitabilityYantai, China, March 30, 2026 — Boan Biotech (6955.HK) today announced its annual result...
Shanghai, March 13, 2026 — Luye Pharma Group today announced a strategic partnership with Sinopharm Group Co. Ltd. (Sinopharm Group) and its subsidiary China National Medicines Corporation Ltd. (Sino...
Shanghai, January 8, 2026 —Luye Pharma Group today announced that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has accepted the New Drug Appli...
Recently, as a partner of the "Peking University Luye Biomedical Innovation Fund," Luye Life Sciences Group was invited to visit Peking University. The delegation, including Mr. Yang Liang, ...
Shanghai, December 7, 2025 – Luye Pharma Group today announced that five new products have been included in the 2025 edition of the National Reimbursement Drug List for Basic Medical Insurance, ...
Boan Biotech today announced that its aflibercept intravitreous injection Boyoujing® has been approved by China’s National Medical Products Administration (NMPA) for the treatment of neovascular...
Boan Biotech today announced that the preliminary results of the ongoing Phase I clinical study for its BA1301, an investigational antibody-drug conjugate (ADC), were recently presented at the 2025 Co...
- New Product Sales Up 32%, International Strategy Upgraded -Shanghai, August 28, 2025 -- Luye Pharma Group (2186.HK) today announced its 2025 half-year results and latest developments. During the rep...
Boan Biotech (6955.HK) today announced its 2025 half-year results and latest developments.During the reporting period, the company's total revenue was RMB 393 million, up 8% YoY, and the contribut...
Yantai, August 8, 2025 –- Boan Biotech announced that China’s National Medical Products Administration (NMPA) has granted marketing approval to its Boyouping®(Dulaglutide Injection), indic...
TOP